October 30, 2019
IQVIA Reports Third-Quarter 2019 Results
Third-quarter revenue $2,769 million Adjusted EBITDA $593 million GAAP Diluted Earnings per Share $0.29; Adjusted Diluted Earnings per Share $1.60…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 30, 2019
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that…
October 30, 2019
Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results
Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA…
October 30, 2019
Aerie Pharmaceuticals appoint new Chief Research & Development Officer
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
October 30, 2019
Cystic Fibrosis Foundation Launches $500 Million Path to a Cure
–Nonprofit issues challenge to accelerate treatments for every person with CF–
October 30, 2019
Can Medicaid Help Seniors Age In Place?
There are many health and safety concerns surrounding seniors living alone. According to the Administration on Aging, approximately 20 percent of men and 36 percent of women over the age of 65 currently live alone, and accidents and close calls are among their biggest risks.
October 30, 2019
EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of…
October 30, 2019
Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019.
October 30, 2019
FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
– Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed…
October 29, 2019
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
Cellectis has had first patient dosed with off-the-Shelf UCARTCS1 product candidate for relapsed/refractory multiple myeloma.